Patents by Inventor John J. Baldwin

John J. Baldwin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antiarrhythmic benzodiazepines
    Patent number: 5595990
    Abstract: Benzo-(1,5)-diazepine derivatives with an amide or urea function in the 3-position are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: March 27, 1995
    Date of Patent: January 21, 1997
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David A. Claremon, Jason M. Elliott, Nigel Liverton, David C. Remy, Harold G. Selnick
  • Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
    Patent number: 5475109
    Abstract: Dioxobutanoic acids substituted with piperidine or similar N-substituted saturated cycloalkyls are found to inhibit the cap-dependent endonuclease of influenza virus. These compounds are useful in the prevention or treatment of infection by influenza virus and the treatment of influenza, either as compound, pharmaceutically acceptable salts,. pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating influenza and methods of preventing or treating infection by influenza virus are also described.
    Type: Grant
    Filed: October 17, 1994
    Date of Patent: December 12, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Harold G. Selnick, Gerald S. Ponticello, John J. Baldwin, Joanne E. Tomassini
  • Furanodiazepines
    Patent number: 5453424
    Abstract: This invention is concerned with novel compounds represented by structural formulae I and II. ##STR1## which are useful in the treatment of cardiac arrhythmia.
    Type: Grant
    Filed: November 22, 1993
    Date of Patent: September 26, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Gerald S. Ponticello, John J. Baldwin, David C. Remy
  • Fibrinogen receptor antagonists
    Patent number: 5451578
    Abstract: Compounds of the invention have the formula: ##STR1## which have fibrinogen receptor antagonist activity, including, for example, ##STR2##
    Type: Grant
    Filed: August 12, 1994
    Date of Patent: September 19, 1995
    Assignee: Merck & Co., Inc.
    Inventors: David A. Claremon, Nigel Liverton, John J. Baldwin
  • Antiarrhythmic benzodiazepines
    Patent number: 5439906
    Abstract: Imidazobenzo-(1,5)-diazepine derivatives with an amide or urea function in the 3-position are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: November 22, 1993
    Date of Patent: August 8, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Robert M. DiPardo, Roger M. Freidinger, John J. Baldwin, David C. Remy
  • Antiarrhythmic benzodiazepines
    Patent number: 5438055
    Abstract: Benzodiazepine derivatives with an amide or urea function in the 3-position are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: November 22, 1993
    Date of Patent: August 1, 1995
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Jason M. Elliott, David A. Claremon, Nigel Liverton, David C. Remy, Harold G. Selnick
  • 3-acylaminobenzodiazepines
    Patent number: 5428157
    Abstract: 3-Acylamino-5-Aminobenzo[1,5]diazepines are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: November 22, 1993
    Date of Patent: June 27, 1995
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David A. Claremon, Jason M. Elliott, Nigel Liverton, David C. Remy, Harold G. Selnick
  • Antiarrhythmic benzodiazepines
    Patent number: 5426185
    Abstract: Benzo-(1,5)-diazepine derivatives with an amide or urea function in the 3-position are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: November 22, 1993
    Date of Patent: June 20, 1995
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David A. Claremon, Jason M. Elliott, Nigel Liverton, David C. Remy, Harold G. Selnick
  • Spirocycles
    Patent number: 5403846
    Abstract: Compounds of the general formula: ##STR1## or a pharmaceutically acceptable salt, hydrate or crystal form enantiomer, diastereomer or mixtures thereof are Class III antiarrhythmic agents.
    Type: Grant
    Filed: November 22, 1993
    Date of Patent: April 4, 1995
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David A. Claremon, Gerald S. Ponticello, Harold G. Selnick
  • Spirocycles
    Patent number: 5382587
    Abstract: Spirocycles of the general structural formulae: ##STR1## wherein: X is O, CH.sub.2 or SO.sub.m ;R.sup.1 is AlkylSO.sub.2 NH--, AlkylO--, AlkylSO.sub.2 --, AlkylCONH--, or NO.sub.2 --;R.sup.2 is --H, --OAlkyl, or --Alkyl;R.sup.3 is --NHCOCH.sub.2 SO.sub.m Phenyl, --NHCOCH.sub.2 SO.sub.m Alkyl,--NHCOC(CH.sub.3).sub.2 OH, or NHSO.sub.2 Alkyl;R.sup.4 and R.sup.5 are --H, or --Alkyl;R.sup.6 is ##STR2## R.sup.7 is --H, --CN, --NHSO.sub.2 Alkyl, --Br, --OAlkyl, --NH.sub.2, --NO.sub.2, --NHCOAlkyl, or NHCONHAlkyl;R.sub.8 is --H, --OH, --CN, --OAlkyl, --CONHAlkyl, --NHSO.sub.2 Alkyl, --NHCOAlkyl, --SO.sub.m Alkyl, or --CO.sub.2 Alkyl;and m is 0-2; or a pharmaceutically acceptable salt, hydrate or crystal form thereof; which are Class III antiarrhythmic agents.
    Type: Grant
    Filed: June 30, 1993
    Date of Patent: January 17, 1995
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David A. Claremon, Jason M. Elliott
  • Tricyclic thienothiopyran carbonic anhydrase inhibitors
    Patent number: 5334591
    Abstract: Conformationally constrained tricyclic thienothiopyran compounds are topically effective carbonic anhydrase inhibitors useful in the treatment of ocular hypertension and glaucoma associated therewith.
    Type: Grant
    Filed: March 4, 1993
    Date of Patent: August 2, 1994
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Kenneth L. Shepard, Gerald S. Ponticello, Theresa M. Williams
  • Tricyclic derivatives of the thienodiazocine and thienothiadiazocine classes of compounds
    Patent number: 5308842
    Abstract: Conformationally constrained tricyclic derivatives of the thienodiazocine and thienothiadiazocine classes of compounds and ring homologs thereof are topically effective carbonic anhydrase inhibitors useful in the treatment of ocular hypertension and glaucoma associated therewith.
    Type: Grant
    Filed: May 10, 1993
    Date of Patent: May 3, 1994
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello
  • Substituted aromatic sulfonamides as antiglaucoma agents
    Patent number: 5308863
    Abstract: Thieno[2,3-b]thiopyran-2-sulfonamides and ring homologs with a hydrophilic substituted-alkyl group adjacent to the thiopyran sulfur are carbonic anhydrase inhibitors topically effective in lowering intraocular pressure.
    Type: Grant
    Filed: June 16, 1992
    Date of Patent: May 3, 1994
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello, Charles N. Habecker, Harold G. Selnick
  • Heterobicyclic sulfonamides
    Patent number: 5276025
    Abstract: Compounds of general formula: ##STR1## are topically effective carbonic anhydrase inhibitors useful in the treatment of ocular hypertension and related disorders such as glaucoma.
    Type: Grant
    Filed: September 9, 1992
    Date of Patent: January 4, 1994
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Jacob M. Hoffman, Jr., James H. Jones, Clarence S. Rooney, Anthony M. Smith
  • Adjuncts in cancer chemotherapy
    Patent number: 5272159
    Abstract: Various cyproheptadine derivatives sensitize multidrug resistant cells to certain chemotherapeutic agents. As such, these cyproheptadine derivatives are useful as adjuncts in the reversal of multidrug resistance in mammalian tumor cells either as compounds, pharmaceutically acceptable salts, or pharmaceutical composition ingredients in combination with anticancer chemotherapeutic agents or compounds.
    Type: Grant
    Filed: December 17, 1991
    Date of Patent: December 21, 1993
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David C. Remy
  • Tricyclic thienothiopyran carbonic anhydrase inhibitors
    Patent number: 5235059
    Abstract: Conformationally constrained tricyclic thienothiopyran compounds are topically effective carbonic anhydrase inhibitors useful in the treatment of ocular hypertension and glaucoma associated therewith.
    Type: Grant
    Filed: October 15, 1991
    Date of Patent: August 10, 1993
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello
  • Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
    Patent number: 5215989
    Abstract: Compounds of structural formula: ##STR1## wherein Ar is an aromatic ring, B is a cyclic moiety fused to Ar of 5-7 members, X and Y are bridging groups, Q is a nitrogen containing heterocycle, R.sup.2 and R.sup.3 are H, substituted or unsubtituted C.sub.1-3 alkyl, C.sub.1-3 alkoxy, N(R).sub.2, halogen, CF.sub.3 or R.sup.5 and R.sup.1 is H or an aryl group.
    Type: Grant
    Filed: July 15, 1991
    Date of Patent: June 1, 1993
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David A. Claremon, Jason M. Elliott, Gerald S. Ponticello, David C. Remy, Harold G. Selnick
  • Substituted 4,5-dihydrothieno(2,3-b)thiophene-2-sulfonamides and 6,6-dioxides thereof
    Patent number: 5216020
    Abstract: Substituted 4,5-dihydrothieno[2,3-b]thiophene-2-sulfonamides and 6,6-dioxides thereof are topically effective carbonic anhydrase inhibitors useful in the treatment of ocular hypertension and glaucoma associated therewith.
    Type: Grant
    Filed: August 9, 1991
    Date of Patent: June 1, 1993
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Kenneth L. Shepard, Ronald J. Hudcosky, Theresa M. Williams
  • Nitrogen-containing spirocycles
    Patent number: 5206240
    Abstract: Spirocycles of general structural formula: ##STR1## are Class III antiarrhythmic agents.
    Type: Grant
    Filed: June 3, 1991
    Date of Patent: April 27, 1993
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Jason M. Elliott, David A. Claremon, Gerald S. Ponticello, David C. Remy, Harold G. Selnick
  • Methods for thrombolytic therapy
    Patent number: 5188830
    Abstract: Certain Factor XIIIa inhibitor compounds have been discovered which have been found to be useful in the lysis of blood clots and thus adaptable for administration in thrombolytic therapy either alone or together with plasminogen activator.
    Type: Grant
    Filed: April 2, 1990
    Date of Patent: February 23, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Joseph G. Atkinson, David A. Claremon, John J. Baldwin, Paul A. Friedman, David C. Remy, Andrew M. Stern